The DOI matches its Crossref record; 253 of the 253 references it cites were found in a registry or an index.
Nrf2/Keap1/ARE signaling: Towards specific regulation
Open accessAbstract
The Nrf2 transcription factor governs the expression of hundreds genes involved in cell defense against oxidative stress, the hallmark of numerous diseases such as neurodegenerative, cardiovascular, some viral pathologies, diabetes and others. The main route for Nrf2 activity regulation is via interactions with the Keap1 protein. Under the normoxia the Keap1 binds the Nrf2 and targets it to the proteasomal degradation, while the Keap1 is regenerated. Upon oxidative stress the interactions between Nrf2 and Keap1 are interrupted and the Nrf2 activates the transcription of the protective genes. Currently, the Nrf2 system activation is considered as a powerful cytoprotective strategy for treatment of different pathologies, which pathogenesis relies on oxidative stress including viral diseases of pivotal importance such as COVID-19. The implementation of this strategy is accomplished mainly through the inactivation of the Keap1 “guardian” function. Two approaches are now developing: the Keap1 modification via electrophilic agents, which leads to the Nrf2 release, and direct interruption of the Nrf2:Keap1 protein-protein interactions (PPI). Because of theirs chemical structure, the Nrf2 electrophilic inducers could non-specifically interact with others cellular proteins leading to undesired effects. Whereas the non-electrophilic inhibitors of the Nrf2:Keap1 PPI could be more specific, thereby widening the therapeutic window.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–253 of 253
CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells
Wang, Q., Ma, J., Lu, Y., Zhang, S., Huang, J., Chen, J., Bei, J.-X., Yang, K., Wu, G., Huang, K., et al. (2017) · Oncogene · doi:10.1038/onc.2017.161 · Cited by 86
Takenobu, T., Tomizawa, K., Matsushita, M., Li, S. T., Moriwaki, A., Lu, Y., & Matsui, H. (2002) · PubMed · Cited by 85
Zhuang, C., Wu, Z., Xing, C., & Miao, Z. (2017) · MedChemComm · doi:10.1039/c6md00500d · Cited by 84 · cited 1×
“many assays [191]) was noticed by several authors [192,193,194].”
Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway
Richardson, B. G., Jain, A. D., Speltz, T. E., & Moore, T. W. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.04.019 · Cited by 83
Mulvaney, K. M., Matson, J. P., Siesser, P. F., Tamir, T. Y., Goldfarb, D., Jacobs, T. M., Cloer, E. W., Harrison, J. S., Vaziri, C., Cook, J. G., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.729418 · Cited by 83
Lu, M., Jiao, Q., Liu, T., Tan, S.-J., Zhou, H.-S., You, Q., & Jiang, Z. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.052 · Cited by 83
Ferrari, M., Zevini, A., Palermo, E., Muscolini, M., Alexandridi, M., Etna, M. P., Coccia, E. M., Fernández-Sesma, A., Coyne, C. B., Zhang, D. D., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01551-20 · Cited by 80
Olagnier, D. P., Lababidi, R. R., Hadj, S. B., Sze, A., Liu, Y., Naidu, S. D., Ferrari, M., Jiang, Y., Chiang, C., Beljanski, V., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.022 · Cited by 79
Townsend, B. E., & Johnson, R. W. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.11.004 · Cited by 78
Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson’s disease – a multicenter study
von Otter, M., Bergström, P., Quattrone, A., Marco, E. V. D., Annesi, G., Söderkvist, P., Wettinger, S. B., Droździk, M., Białecka, M. A., Nissbrandt, H., et al. (2014) · BMC Medical Genetics · doi:10.1186/s12881-014-0131-4 · Cited by 78
Nrf2: a modulator of Parkinson’s disease?
Todorovic, M., Wood, S. A., & Mellick, G. D. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1563-0 · Cited by 78
Nrf2 as a therapeutic target for rheumatic diseases
Ferrándiz, M. L., Nácher-Juan, J., & Alcaraz, M. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.04.010 · Cited by 77
Zinovkin, R. A., & Grebenchikov, O. A. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297920070111 · Cited by 77
Emerging landscape of cell penetrating peptide in reprogramming and gene editing
Liu, H., Zeng, F., Zhang, M. X., Huang, F., Wang, J., Guo, J., Liu, C.-B., & Wang, H. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.002 · Cited by 73
Nrf2 gene promoter polymorphism is associated with ulcerative colitis in a Japanese population.
Arisawa, T., Tahara, T., Shibata, T., Nagasaka, M., Nakamura, M., Kamiya, Y., Fujita, H., Yoshioka, D., Okubo, M., Sakata, M., et al. (2008) · PubMed · Cited by 71
Schachtele, S. J., Hu, S., & Lokensgard, J. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036216 · Cited by 70
Hahm, E., & Singh, S. V. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0250 · Cited by 69
Rising levels of atmospheric oxygen and evolution of Nrf2
Gaćeša, R., Dunlap, W. C., Barlow, D. J., Laskowski, R. A., & Long, P. F. (2016) · Scientific Reports · doi:10.1038/srep27740 · Cited by 67
Monitoring and deciphering protein degradation pathways inside cells
Daniels, D. L., Riching, K. M., & Urh, M. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.12.001 · Cited by 67
Herengt, A., Thyrsted, J., & Holm, C. K. (2021) · Antioxidants · doi:10.3390/antiox10091491 · Cited by 66
Зенков, Н. К., Kozhin, P. M., Владимирович, Ч. А., Мартинович, Г. Г., Кандалинцева, Н. В., & Брониславовна, М. Е. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917050030 · Cited by 64
Komaravelli, N., Ansar, M., Garofalo, R., & Casola, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.380 · Cited by 62
Cheng, Y., Lin, Y.-S., Chen, C., Tsai, T.-T., Tsai, C., Wu, Y., Ou, Y.-D., Chu, Y., Wang, J., Yu, C.-Y., et al. (2016) · Scientific Reports · doi:10.1038/srep32000 · Cited by 60
Bender, D., & Hildt, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184659 · Cited by 59
Nrf2 as a potential target for Parkinson’s disease therapy
Niu, Y., Zhang, J., & Dong, M. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02071-5 · Cited by 59
Yang, C., Tan, Y., Yang, G.-Z., Zhang, J., Pan, Y., Liu, C., Fu, J., Chen, Y., Ding, Z., Dong, L., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151208 · Cited by 56
Binding thermodynamics and kinetics guided optimization of potent Keap1–Nrf2 peptide inhibitors
Lu, M.-C., Chen, Z.-Y., Wang, Y.-L., Jiang, Y.-L., Yuan, Z.-W., You, Q.-D., & Jiang, Z.-Y. (2015) · RSC Advances · doi:10.1039/c5ra16262a · Cited by 55 · cited 1×
“binder (Ac-LDPETGEYL-OH, Kd = 42 nM [214]) as moiety to recruit Keap1 in vivo in order to downregulate cellular target protein, Tau”
BackgroundAssociation of NFE2L2 and KEAP1 haplotypes with amyotrophic lateral sclerosis
Bergström, P., von Otter, M., Nilsson, S., Nilsson, A.-C., Nilsson, M., Andersen, P. M., Hammarsten, O., & Zetterberg, H. (2013) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2013.839708 · Cited by 53
Venci, J. V., & Gandhi, M. A. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013509232 · Cited by 52
FAM129B, an antioxidative protein, reduces chemosensitivity by competing with Nrf2 for Keap1 binding
Cheng, K., Lin, R., Cheng, J., Wang, S., Yu, J., Wu, J., Liang, Y., Hsu, H.-M., Yu, J., & Yu, A. L.-T. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.022 · Cited by 52
Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis
Hosseini, A., Masjedi, A., Baradaran, B., Hojjat‐Farsangi, M., Ghalamfarsa, G., Anvari, E., & Jadidi‐Niaragh, F. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27930 · Cited by 51
Zhou, X., Zhu, C.-Y., Wu, Z., Guo, X., & Zou, W. (2019) · Oncogene · doi:10.1038/s41388-019-0698-5 · Cited by 51
Structural analysis of the complex of Keap1 with a prothymosin α peptide
Padmanabhan, B., Nakamura, Y., & Yokoyama, S. (2008) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309108004995 · Cited by 50
Transcription factors: Time to deliver
Ulasov, A. V., Rosenkranz, A. A., & Sobolev, A. S. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.004 · Cited by 45
Self-citation竹信, 俊. (2003) · Institutional Repositories DataBase (IRDB) · Cited by 44
Sulforaphane Inhibits HIV Infection of Macrophages through Nrf2
Furuya, A. K. M., Sharifi, H. J., Jellinger, R. M., Cristofano, P., Shi, B., & de Noronha, C. M. C. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005581 · Cited by 44
Non-Canonical Activation of NRF2: New Insights and Its Relevance to Disease
Dodson, M. B., & Zhang, D. D. (2017) · Current Pathobiology Reports · doi:10.1007/s40139-017-0131-0 · Cited by 44
The Keap1–Nrf2 protein–protein interaction: A suitable target for small molecules
Schmoll, D., Engel, C. K., & Glombik, H. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.10.001 · Cited by 43
Conserved solvent and side-chain interactions in the 1.35 Å structure of the Kelch domain of Keap1
Beamer, L. J., Li, X., Bottoms, C. A., & Hannink, M. (2005) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905022626 · Cited by 42
A novel strategy to activate cytoprotective genes in the injured brain
Zhao, J., Redell, J. B., Moore, A. N., & Dash, P. K. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.046 · Cited by 33
The prognostic value of p62 in solid tumor patients: a meta-analysis
Ruan, H., Xu, J., Wang, L., Zhao, Z., Kong, L., Lan, B., & Li, X. (2017) · Oncotarget · doi:10.18632/oncotarget.23101 · Cited by 30
RA-839, a selective agonist of Nrf2/ARE pathway, exerts potent anti-rotaviral efficacy in vitro
Patra, U., Mukhopadhyay, U., Sarkar, R., Mukherjee, A., & Chawla‐Sarkar, M. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.11.009 · Cited by 30
Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction
Colarusso, S., Simone, D. D., Frattarelli, T., Andreini, M., Cerretani, M., Missineo, A., Moretti, D., Tambone, S., Kempf, G., Augustin, M. A., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115738 · Cited by 29
Wan, Z., Jiang, T., Shi, Y., Pan, Y., Lin, Y., Ma, Y., Yang, C., Feng, X., Huang, L., Kong, X., et al. (2019) · Hepatology · doi:10.1002/hep.30962 · Cited by 28
Guntas, G., Lewis, S. M., Mulvaney, K. M., Cloer, E. W., Tripathy, A., Lane, T. R., Major, M. B., & Kuhlman, B. A. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv055 · Cited by 26
Chemical Tuning Enhances Both Potency Toward Nrf2 and In Vitro Therapeutic Index of Triterpenoids
Copple, I. M., Shelton, L. M., Walsh, J., Kratschmar, D. V., Lister, A., Odermatt, A., Goldring, C. E., Dinkova‐Kostova, A. T., Honda, T., & Park, B. K. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu080 · Cited by 26
NFE2L2 variations reduce antioxidant response in patients with Parkinson disease
Gui, Y., Zhang, L., Lv, W., Zhang, W., Zhao, J.-J., & Hu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.7353 · Cited by 23
The Keap1-Nrf2 pathway: From mechanism to medical applications
Baird, L., & Yamamoto, M. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-818606-0.00009-2 · Cited by 21
Karttunen, M., Choy, W., & Cino, E. A. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b03295 · Cited by 20
The prognostic value of NRF2 in solid tumor patients: a meta-analysis
Wang, L., Zhang, C., Qin, L., Xu, J., Li, X., Wang, W., Kong, L., Zhou, T., & Li, X. (2017) · Oncotarget · doi:10.18632/oncotarget.19838 · Cited by 12
Jo, J., Ibrahim, L. H., Iaconelli, J., Kwak, J., Kumar, M., Jung, Y., Lairson, L. L., Chatterjee, A. K., Schultz, P. G., Bollong, M. J., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104614 · Cited by 10
Third oral MS drug wins FDA nod
Sheridan, C. (2013) · Nature Biotechnology · doi:10.1038/nbt0513-373a · Cited by 6
Todorovic, M., & Mellick, G. D. (2016) · InTech eBooks · doi:10.5772/65450 · Cited by 1
Cited by
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Signal amplification in the KEAP1-NRF2-ARE antioxidant response pathway
Liu, S., Pi, J., & Zhang, Q. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102389 · Cited by 443
Mitochondria: It is all about energy
Casanova, A., Wevers, A., Navarro-Ledesma, S., & Pruimboom, L. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1114231 · Cited by 303
Cheng, X., Huang, J., Li, H., Zhao, D., Liu, Z., Zhu, L., Zhang, Z., & Peng, W. (2024) · Phytomedicine · doi:10.1016/j.phymed.2023.154887 · Cited by 286
Tkaczenko, H., & Kurhaluk, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031098 · Cited by 80
“Therapeutic strategies focusing on the transcriptional activation of Nrf2 have been outlined in several studies [119–121].”
Metadata
- Authors
- Ulasov, A. V., Rosenkranz, A. A., Georgiev, G. P., & Sobolev, A. S.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 291
- Pages
- 120111
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W3209255096
- Cited by
- 508
- References
- 253
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.